WGS250117P100000
- 10.50
- 0.000.00%
GeneDx Holdings Newsroom
Craig-Hallum Maintains GeneDx Holdings(WGS.US) With Buy Rating
GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers
GeneDx Continues Its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients
GeneDx Holdings Is Maintained at Buy by TD Cowen
GeneDx Hldgs Analyst Ratings
TD Cowen Maintains GeneDx Holdings(WGS.US) With Buy Rating, Raises Target Price to $118
GeneDx Holdings (WGS) Surges 13.2%: Is This an Indication of Further Gains?
Trending Stocks Today | MultiSensor AI Shoots up 38% Post-Market
GeneDx Holdings (NASDAQ:WGS) Has Debt But No Earnings; Should You Worry?
Resources Connection, SPS Commerce And 3 Stocks To Watch Heading Into Friday
GeneDx Names Dechairo as First Chief Operating Officer
GeneDx Strengthens Executive Leadership Team With Bryan Dechairo Named Chief Operating Officer >WGS
GeneDx Strengthens Executive Leadership Team With Bryan Dechairo Named Chief Operating Officer
Top-rated Smaller Defensive Stocks After Societe Generale Permabear Takes Contrarian View
Institutional Investors Control 59% of GeneDx Holdings Corp. (NASDAQ:WGS) and Were Rewarded Last Week After Stock Increased 3.5%
GeneDx Announces Biogen, Praxis Precision Medicines And Stoke Therapeutics As The Founding Partners To Its Patient Access Program For Pediatric Epilepsy, Which Provides Access To Whole Exome Sequencing.
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients With New Partners
AppLovin, MicroStrategy, and 28 Other Stocks That Could Be Bubbles
Sleep Number, Getty Images, and More Stocks See Action From Activist Investors -- Barrons.com
Insider Sale: CHIEF FINANCIAL OFFICER of $WGS (WGS) Sells 2,108 Shares